Paladini Giorgio, Pecorari Paolo, De Sabbata Giovanni, Sammartini Chiara
II Divisione di Medicina Interna e Servizio di Ematologia, Ospedali Riuniti, Trieste.
Recenti Prog Med. 2004 Feb;95(2):108-19.
The myelodysplastic syndromes (MDS) are a heterogeneous group of haematological disorders with an indolent course, but invariable leukaemic transformation. Despite this, data on MDS are seldom collected by cancer registries and unbiased results from population-based studies remain rare. For decades, MDS has been a most challenging disease for biologists as well as for physicians and haematologists in terms of both diagnosis and treatment. The therapeutic dilemma that confronts the management of patients with MDS is illustrated by the absence both in Italy and in USA of an approved-agent with a specific indication for this disease. However, because of improving in prognostic instruments and because of continuing research into new treatment strategies, patients with MDS now have more articulate options than even before, with a consequent better chance of long-term survival.
骨髓增生异常综合征（MDS）是一组异质性血液系统疾病，病程进展缓慢，但白血病转化不可避免。尽管如此，癌症登记机构很少收集MDS的数据，基于人群研究的无偏倚结果仍然很少见。几十年来，MDS无论是在诊断还是治疗方面，对生物学家以及内科医生和血液学家来说都是极具挑战性的疾病。意大利和美国均没有针对该疾病的特定适应症的获批药物，这凸显了MDS患者管理中面临的治疗困境。然而，由于预后评估手段的改进以及对新治疗策略的持续研究，MDS患者现在比以往有了更清晰明确的选择，从而有了更好的长期生存机会。
